Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 1873-1880

  Kim, Julian O ^a,b,c,d   Gazala, Sayf ^a   Razzak, Rene ^a   Guo, Linghong ^a,c   Ghosh, Sunita ^a,c   Roa, Wilson H ^a,c   Bédard, Eric L R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d CancerCare   (Canada)

Author keywords

Bronchoalveolar lavage; Cancer detection; Micro RNA profiling; Non small cell lung cancer; Sputum

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MICRORNA; MICRORNA 143; MICRORNA 155; MICRORNA 21; MICRORNA 210; MICRORNA 372; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG LAVAGE; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPUTUM; SQUAMOUS CELL LUNG CARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84928398583     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Molina JR, Yang P, Cassivi SD, Schild SE, and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5): 584-94, 2008.
2. National Cancer Institute: PDQ non-small cell lung cancer treatment. Bethesda, MD: National Cancer Institute; 2013.
3. Schreiber G and McCrory DC: Performance characteristics of different modalities for diagnosis of suspected lung cancer: Summary of published evidence. Chest 123(1 Suppl): 115S-28S, 2003.
4. Wallace JM and Deutsch AL: Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration for evaluating the solitary pulmonary nodule. Chest 81(6): 665-71, 1982.
5. Gasparini S, Ferretti M, Secchi EB, Baldelli S, Zuccatosta L and Gusella P: Integration of transbronchial and percutaneous approach in the diagnosis of peripheral pulmonary nodules or masses. experience with 1.027 consecutive cases. Chest 108(1): 131-7, 1995.
6. Shirakawa T, Imamura F, Hamamoto J, Honda I, Fukushima K, Sugimoto M and Shirkakusa T: Usefulness of endobronchial ultrasonography for transbronchial lung biopsies of peripheral lung lesions. Respiration 71(3): 260-8, 2004.
7. Choi CM, Um SW, Yoo CG, Kim YW, Han SK, Shim YS and Lee, CT: Incidence and risk factors of delayed pneumothorax after transtho racic needle biopsy of the lung. Chest 126(5): 1516-21, 2004.
8. Agusti C, Xaubet A, Monton C, Sole M, Soler N, Carrion M and Rodriguez Roisin R: Induced sputum in the diagnosis of peripheral lung cancer not visible endoscopically. Respir Med 95(10): 822-8, 2001.
9. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116(2): 281-97, 2004.
10. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-66, 2006.
11. Etheridge A, Lee I, Hood L, Galas D and Wang K: Extracellular microRNA: A new source of biomarkers. Mutat Res 717(1-2): 85-90, 2011.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 105(30): 10513-8, 2008.
13. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass S and Jiang F: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67(2): 170-6, 2010.
14. Mraz M, Malinova K, Mayer J and Pospisilova S: MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun 390(1): 1-4, 2009.
15. Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC and Wang ZX: MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol 56(6): 645-54, 2012.
16. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R and Mansukhani M: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27(12): 2030-7, 2009.
17. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, Zhuang R, Zhang Y, Hu H, Liu C, Xu L, Wang J, Shen H, Zhang j, Zen K and Zhang CY: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive bio-markers for nonsmall cell lung cancer diagnosis. Int J Cancer 130(7): 1620-8, 2012.
18. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E and Califano JA: Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 7(2): e32307, 2012.
19. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL and Jiang F: Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 91(4): 579-87, 2011.
20. Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, Gazala S, Ghosh S, Wong E, Joy AA, Xing JZ and Bedard EL: Sputum microRNA profiling: A novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 35(5): E271, 2012.
21. Xing L, Todd NW, Yu L, Fang H and Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 23(8): 1157-64, 2010.
22. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL and Jiang F: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127(12): 2870-8, 2010.
23. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA and Jiang F: Analysis of microRNAs in sputum to improve computed tomo graphy for lung cancer diagnosis. J Thorac Oncol 9(1): 33-40, 2014.
24. th ed. New York, NY: Springer. 253-66, 2010.
25. Alberta Health Services: Non-small Cell Lung Cancer: Stage I. Available at: http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-lu001-nsclc-stage1.pdf.
26. Alberta Health Services: Non-Small Cell Lung Cancer: Stage II. Available at: http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-algorithm-nsclc-stage2.pdf.
27. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E and Olson EN: Modulation of K-ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 18(3): 282-93, 2010.
28. Liu ZL, Wang H, Liu J and Wang ZX: MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radio-resistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Bioche. 372(1-2): 35-45, 2013.
29. Zhang N, Su Y and Xu L: Targeting PKCepsilon by miR-143 regulates cell apoptosis in lung cancer. FEBS Lett 587(22): 3661-7, 2013.
30. Higgs G and Slack F: The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma. 3(1):17,9113-3-17, 2013.
31. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouyssegur J, Gounon P, Hofman P, Barbry P and Mari B: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18(3): 465-78, 2011.
32. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM and Mari B: MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4: e544, 2013.
33. Lai JH, She TF, Juang YM, Tsay YG, Huang AH, Yu SL, Chen JJ and Lai CC: Comparative proteomic profiling of human lung adenocarcinoma cells (CL 1-0) expressing miR-372. Electrophoresis 33(4): 675-88, 2012.
34. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J and Sidransky D: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91(4): 332-9, 1999.
35. Winawer SJ, Flehinger BJ, Schottenfeld D and Miller DG: Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85(16): 1311-8, 1993.
36. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF and Selby JV: Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics. J Natl Cancer Inst 99(19): 1462-70, 2007.